Cargando…
An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma
Introduction: Fibrosis, a primary cause of hepatocellular carcinoma (HCC), is intimately associated with inflammation, the tumor microenvironment (TME), and multiple carcinogenic pathways. Currently, due to widespread inter- and intra-tumoral heterogeneity of HCC, the efficacy of immunotherapy is li...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712696/ https://www.ncbi.nlm.nih.gov/pubmed/34970594 http://dx.doi.org/10.3389/fmolb.2021.766609 |
_version_ | 1784623609980911616 |
---|---|
author | Liu, Long Liu, Zaoqu Meng, Lingfang Li, Lifeng Gao, Jie Yu, Shizhe Hu, Bowen Yang, Han Guo, Wenzhi Zhang, Shuijun |
author_facet | Liu, Long Liu, Zaoqu Meng, Lingfang Li, Lifeng Gao, Jie Yu, Shizhe Hu, Bowen Yang, Han Guo, Wenzhi Zhang, Shuijun |
author_sort | Liu, Long |
collection | PubMed |
description | Introduction: Fibrosis, a primary cause of hepatocellular carcinoma (HCC), is intimately associated with inflammation, the tumor microenvironment (TME), and multiple carcinogenic pathways. Currently, due to widespread inter- and intra-tumoral heterogeneity of HCC, the efficacy of immunotherapy is limited. Seeking a stable and novel tool to predict prognosis and immunotherapy response is imperative. Methods: Using stepwise Cox regression, least absolute shrinkage and selection operator (LASSO), and random survival forest algorithms, the fibrosis-associated signature (FAIS) was developed and further validated. Subsequently, comprehensive exploration was conducted to identify distinct genomic alterations, clinical features, biological functions, and immune landscapes of HCC patients. Results: The FAIS was an independent prognostic predictor of overall survival and recurrence-free survival in HCC. In parallel, the FAIS exhibited stable and accurate performance at predicting prognosis based on the evaluation of Kaplan–Meier survival curves, receiver operator characteristic curves, decision curve analysis, and Harrell’s C-index. Further investigation elucidated that the high-risk group presented an inferior prognosis with advanced clinical traits and a high mutation frequency of TP53, whereas the low-risk group was characterized by superior CD8(+) T cell infiltration, a higher TIS score, and a lower TIDE score. Additionally, patients in the low-risk group might yield more benefits from immunotherapy. Conclusion: The FAIS was an excellent scoring system that could stratify HCC patients and might serve as a promising tool to guide surveillance, improve prognosis, and facilitate clinical management. |
format | Online Article Text |
id | pubmed-8712696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87126962021-12-29 An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma Liu, Long Liu, Zaoqu Meng, Lingfang Li, Lifeng Gao, Jie Yu, Shizhe Hu, Bowen Yang, Han Guo, Wenzhi Zhang, Shuijun Front Mol Biosci Molecular Biosciences Introduction: Fibrosis, a primary cause of hepatocellular carcinoma (HCC), is intimately associated with inflammation, the tumor microenvironment (TME), and multiple carcinogenic pathways. Currently, due to widespread inter- and intra-tumoral heterogeneity of HCC, the efficacy of immunotherapy is limited. Seeking a stable and novel tool to predict prognosis and immunotherapy response is imperative. Methods: Using stepwise Cox regression, least absolute shrinkage and selection operator (LASSO), and random survival forest algorithms, the fibrosis-associated signature (FAIS) was developed and further validated. Subsequently, comprehensive exploration was conducted to identify distinct genomic alterations, clinical features, biological functions, and immune landscapes of HCC patients. Results: The FAIS was an independent prognostic predictor of overall survival and recurrence-free survival in HCC. In parallel, the FAIS exhibited stable and accurate performance at predicting prognosis based on the evaluation of Kaplan–Meier survival curves, receiver operator characteristic curves, decision curve analysis, and Harrell’s C-index. Further investigation elucidated that the high-risk group presented an inferior prognosis with advanced clinical traits and a high mutation frequency of TP53, whereas the low-risk group was characterized by superior CD8(+) T cell infiltration, a higher TIS score, and a lower TIDE score. Additionally, patients in the low-risk group might yield more benefits from immunotherapy. Conclusion: The FAIS was an excellent scoring system that could stratify HCC patients and might serve as a promising tool to guide surveillance, improve prognosis, and facilitate clinical management. Frontiers Media S.A. 2021-12-14 /pmc/articles/PMC8712696/ /pubmed/34970594 http://dx.doi.org/10.3389/fmolb.2021.766609 Text en Copyright © 2021 Liu, Liu, Meng, Li, Gao, Yu, Hu, Yang, Guo and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Liu, Long Liu, Zaoqu Meng, Lingfang Li, Lifeng Gao, Jie Yu, Shizhe Hu, Bowen Yang, Han Guo, Wenzhi Zhang, Shuijun An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title_full | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title_fullStr | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title_full_unstemmed | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title_short | An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma |
title_sort | integrated fibrosis signature for predicting survival and immunotherapy efficacy of patients with hepatocellular carcinoma |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712696/ https://www.ncbi.nlm.nih.gov/pubmed/34970594 http://dx.doi.org/10.3389/fmolb.2021.766609 |
work_keys_str_mv | AT liulong anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT liuzaoqu anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT menglingfang anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT lilifeng anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT gaojie anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT yushizhe anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT hubowen anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT yanghan anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT guowenzhi anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT zhangshuijun anintegratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT liulong integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT liuzaoqu integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT menglingfang integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT lilifeng integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT gaojie integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT yushizhe integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT hubowen integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT yanghan integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT guowenzhi integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma AT zhangshuijun integratedfibrosissignatureforpredictingsurvivalandimmunotherapyefficacyofpatientswithhepatocellularcarcinoma |